Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and Amgen (AMGN)

Tipranks - Tipranks - Tue Apr 7, 7:46PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pro Medicus Limited (PMCUF) and Amgen (AMGN) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Pro Medicus Limited (PMCUF)

In a report released yesterday, Laura Sutcliffe from Citi maintained a Buy rating on Pro Medicus Limited, with a price target of A$245.00. The company’s shares closed last Thursday at $83.00, close to its 52-week low of $64.91.

According to TipRanks.com, Sutcliffe is a 3-star analyst with an average return of 1.4% and a 51.0% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Telix Pharmaceuticals, and Ramsay Health Care. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pro Medicus Limited with a $153.94 average price target, which is an 85.5% upside from current levels. In a report issued on March 24, MA Financial Group also upgraded the stock to Buy with a A$145.03 price target.

See Insiders’ Hot Stocks on TipRanks >>

Amgen (AMGN)

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen yesterday and set a price target of $420.00. The company’s shares closed last Monday at $342.57, close to its 52-week high of $346.85.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 23.3% and a 58.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Terns Pharmaceuticals, and Ionis Pharmaceuticals. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $369.16, a 6.9% upside from current levels. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $385.00 price target.

Read More on PMCUF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).